Clinical Trials · NCT00130403

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

Name: OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Teriparatide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Sanofi
Enrollment: 290
Start date: Mar 2004
Locations: 7 sites, 7 countries
Primary endpoint: Compare the PTH-associated change from baseline at Month 3 of procollagen peptide P1NP, in subjects previously treated with Risedronate or Alendronate

View Teriparatide compound reference